China Junshi's potential COVID-19 drug shows promise in small trial - SABC News - Breaking news, special reports, world, business, sport coverage of all South African current events. Africa's news leader.

  • 📰 SABCNews
  • ⏱ Reading Time:
  • 31 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 16%
  • Publisher: 51%

Brasil Notícia Notícia

Brasil Últimas Notícias,Brasil Manchetes

An antiviral oral drug being co-developed by Shanghai Junshi Biosciences’ subsidiary and other Chinese institutes showed early promise in speeding the clearing of virus in COVID-19 patients…

An experimental COVID-19 treatment pill, called molnupiravir and being developed by Merck & Co Inc and Ridgeback Biotherapeutics LP, is seen in this undated handout photo released by Merck & Co Inc and obtained by Reuters May 17, 2021.An experimental COVID-19 treatment pill, called molnupiravir and being developed by Merck & Co Inc and Ridgeback Biotherapeutics LP, is seen in this undated handout photo released by Merck & Co Inc and obtained by Reuters May 17, 2021.

The drug, called VV116, is a derivative of Gilead SciencesInc’s COVID-19 drug remdesivir and was approved for use in moderate to severe cases in Uzbekistan last year. Participants were given either the five-day course oral drug along with standard treatment or standard treatment only, researchers said in a paper Emerging Microbes & Infections.

Limitations of the study include the small trial size and a higher portion of participants in the control group reporting symptoms, which could result in potential bias that researchers had to adjust with the statistical model, the paper said.

 

Obrigado pelo seu comentário. Seu comentário será publicado após ser revisado.

A nother drug quickly made

I am super excited right now, I can now pay my bills and take good care of my family.. Thank you for bringing happiness to my home with just $5000 i got $50,000 in 7days Williamchurch07

Lmao

yup/// pfizer's pill is also reaylly successfull.. at killing people.. orally this time...

Resumimos esta notícia para que você possa lê-la rapidamente. Se você se interessou pela notícia, pode ler o texto completo aqui. Consulte Mais informação:

 /  🏆 37. in BR

Brasil Últimas Notícias, Brasil Manchetes